A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2019-04-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known
as galunisertib administered in combination with the anti-programmed cell death-ligand 1
(PD-L1) antibody durvalumab in participants with refractory metastatic pancreatic cancer.